Insider filing · HALO
Nicole LaBrosse
SVP, CHIEF FINANCIAL OFFICER
profile →
Halozyme Therapeutics, Inc.
HALO · Healthcare · 39 filings in 24 months
ticker →
Nicole LaBrosse sold $1.5M of Halozyme Therapeutics (HALO)
Executed Sep 10 2025, disclosed Sep 11 2025, 1 day later.
Value, as filed
$1.5M
20,000 sh across 2 lots
Executed
Sep 10 2025
the trade date, as filed
Disclosed
Sep 11 2025
1 day after the trade
Return, 21 sessionsiFrom the disclosed entry session; derived
–
purchases only
Returns are measured on stock purchases only.
The filer
NLNicole LaBrosse (SVP, CHIEF FINANCIAL OFFICER) filed 1 Form 4 report in the trailing twelve months (0 purchases, 1 sale), most often in Halozyme Therapeutics, Inc. (HALO). The largest single filing was $149K of HALO (1,913 sh × $77.83, as filed), executed Sep 22 2025.
The name
HALOHealthcare · Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in th…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→Other filings by Nicole LaBrosse in HALO
HALOSALE
Halozyme Therapeutics, Inc.
$149K1,913 sh × $77.83
Exec Sep 22 2025
Filed Sep 23 2025 · 5:30 PM ET